Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CTT Pharmaceutical HoldingsCTTH -0.13% 10-Year ROIIC % is -527.35 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 860 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks worse than 98.37% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
CTT Pharmaceutical Holdings's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was -527.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for CTT Pharmaceutical Holdings's 10-Year ROIIC % or its related term are showing as below:
CTTH's 10-Year ROIIC % is ranked worse than 98.37% of 860
companies
in the Drug Manufacturers industry
Industry Median: 4.41
vs CTTH: -527.35
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
CTT Pharmaceutical Holdings 10-Year ROIIC % Related Terms
CTT Pharmaceutical Holdings 10-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTTH vs BUDZ, SBFM, PRFX: 10-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTT Pharmaceutical Holdings 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where CTT Pharmaceutical Holdings's 10-Year ROIIC % falls into.
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -0.154 (Dec. 2025) - -1.446 (Dec. 2015) )
/
( 0.09 (Dec. 2025) - 0.335 (Dec. 2015) )
=
1.292
/
-0.245
=
-527.35%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
CTT Pharmaceutical Holdings (CTTH) has a 10-Year ROIIC % of -527.35 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on CTT Pharmaceutical Holdings and its competitors. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #846 out of 860 companies in the Drug Manufacturers industry, placing it in the top 98.4%.
Is CTT Pharmaceutical Holdings' 10-Year ROIIC % too high?
CTT Pharmaceutical Holdings' current 10-Year ROIIC % is -527.35. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #846 out of 860 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CTT Pharmaceutical Holdings' 10-Year ROIIC % compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #846 out of 860 companies for 10-Year ROIIC %. This places CTT Pharmaceutical Holdings in the lower half of its industry. The industry median 10-Year ROIIC % is 4.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.41, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on CTT Pharmaceutical Holdings and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current 10-Year ROIIC % is -527.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current 10-Year ROIIC % of -527.35. The current 10-Year ROIIC % is -527.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current 10-Year ROIIC % is -527.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTTH has been successfully added to your 
